Navigation Links
Buprenorphine is better than methadone for opioid dependence in pregnant women, study shows

Using buprenorphine instead of methadone the current standard of care to treat opioid-dependent pregnant women may result in healthier babies, suggests new findings from an international team led by Johns Hopkins researchers and published in the Dec. 9 issue of the New England Journal of Medicine.

Babies born to mothers taking buprenorphine instead of methadone to counter heroin and/or prescription opioid addiction were likely to need less morphine to deal with drug withdrawal symptoms, spent half as much time in the hospital after delivery and recovered from neonatal abstinence syndrome in half as much time, the study found. Neonatal abstinence syndrome, caused when a fetus is exposed to heroin and/or prescription opioids in the womb, can cause hyperirritability and autonomic nervous system dysfunction, often requiring medication and extended hospital stays for babies born with it.

"In newborns, buprenorphine produces a milder withdrawal than methadone," says study leader Hendree Jones, Ph.D., a professor of psychiatry and behavioral sciences at the Johns Hopkins University School of Medicine. "Our results support the use of buprenorphine as the treatment of choice for opioid dependence in pregnant women."

"The use of buprenorphine as an alternative treatment for opioid dependence during pregnancy had not been well studied," she adds, "making this research important in showing that buprenorphine is a better treatment option than methadone."

Jones cautions that buprenorphine is not for every opioid-dependent pregnant woman. Future research will focus on which drug is right for which type of patient, she says.

The study, an eight-site, double-blind, randomized, controlled trial titled The Maternal Opioid Treatment: Human Experimental Research (MOTHER) project, compared buprenorphine and methadone in the comprehensive care of 175 opioid-dependent women, ages 18 to 40, who were six to 30 weeks' pregnant.

Although not specifically FDA approved for such use, methadone, a synthetic opiate, is the accepted and recommended treatment for opioid dependence during pregnancy. Patients including pregnant women are prescribed methadone in an effort to keep them away from dangerous and illegal street drugs, including heroin, and the risky life issues associated with procuring and taking illegal drugs. Buprenorphine, a newer compound, is comparable to methadone, and both create similar side effects and outcomes for the mother.

Study participants received extensive prenatal and postnatal care and monitoring. Their care plans included psychological evaluations, blood work, sonograms, daily clinic visits, weekly questionnaires, a non-stress test, case management, and group and individual counseling. The mothers and newborns also were monitored for 28 days following delivery.


Contact: Karen Tong
Johns Hopkins Medical Institutions

Related medicine news :

1. UTHealth study suggests private insurers control health care spending better than Medicare
2. Good grades in high school lead to better health, study finds
3. Cognitively-impaired human research subjects need better protection
4. Contaminated Butter Points to Need for Better Surveillance, Study Says
5. Littlest Kids in Big Day-Care Centers May Have Better Health Later On
6. Better imaging from bench to bedside
7. Active surveillance for low-risk prostate cancer may offer better quality-of-life
8. Better Outcomes Seen With Early Rheumatoid Arthritis Diagnosis
9. Screening tool may better identify heart disease in African-Americans
10. Work Teams Who Share Negative Emotions Better at Problem-Solving
11. Better Helmet Design Might Lower Soldiers Risk for Brain Injury
Post Your Comments:
(Date:12/1/2015)... Francisco, CA (PRWEB) , ... December 01, 2015 ... ... Behavioral Health Center of Excellence (BHCOE) today announced that the organization has awarded ... in San Francisco, with a Distinguished Award. The award celebrates exceptional special needs ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... today announced it has been awarded a fixed price per sprint agile development ... contract, valued at $34 million over five years, provides software engineering, infrastructure, as ...
(Date:12/1/2015)... ... December 01, 2015 , ... TCS Healthcare Technologies (TCS), ... population health arenas, is pleased to announce that VIP Care Services, a Caprock ... implemented the ACUITY Complete Care™ Management to back their collaborative catastrophic case management ...
(Date:12/1/2015)... ... 01, 2015 , ... XTC Semifinals 2016 - CES, Las Vegas, Nevada ... Vegas for CES 2016, the world’s largest Consumer Electronic Show, where they will present ... Founding Partner of Pacific Investments Veronica Serra, and venture capitalist Tim Draper among many ...
(Date:12/1/2015)... ... 01, 2015 , ... With FCPX Overlay: Grit , users can apply ... the possibilities are truly endless, all with a click of a mouse. Each user ... horizontal flip, depth of field and more, all within Final Cut Pro X. , ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... , Dec. 1, 2015  CytoSorbents Corporation (NASDAQ: ... commercializing its CytoSorb® blood purification technology to reduce ... world, today announced that Dr. Phillip Chan ... to participate in the LD Micro Main Event ... Conference, both of which will be held in ...
(Date:12/1/2015)... BOULDER, Colo. , Dec. 1, 2015 ... ARRY ) today announced that its Chief ... present at the Oppenheimer Annual Healthcare Conference ... to participate in the conference through a ... , --> ...
(Date:12/1/2015)... Dec. 1, 2015 Assurex Health, Inc. ... test giving healthcare providers an expanded range of ... patients suffering from depression, anxiety, bipolar disorder, posttraumatic ... conditions. i .   ... With the addition of two new drug classes, ...
Breaking Medicine Technology: